巨头疯狂押注!微生物发酵是生物药行业下一座金矿

Ofweek维科网
Yesterday

当生物制药行业内接连诞生出“ADC(抗体偶联药物)”、“GLP-1减肥药”、“细胞免疫治疗”等大热赛道时,微生物发酵这一在传统认知中被视为“老工具”的技术也正在经历革命性蜕变。6月9日,维升药业核心产品——新型长效生长激素隆培促生长素,商业化批次的技术转移项目正式落地药明生物成都微生物商业化生产基地,将成为该基地投产后的“首单”商业化落地成果。药明生物是国内少有的兼具多肽、细胞因子、酶等重组蛋白...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10